Clinical trial
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With…
NCT00429091 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00429091 |
|---|---|
| Title | A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Attention-Deficit/Hyperactivity Disorder, ADHD |
| Intervention type | Drug |
| Interventions | ABT-894, atomoxetine, placebo |
| Enrollment | 243 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2007 |
| First posted | Jan 31, 2007 |
| Last update posted | Nov 2, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: